Prof. Charles Craddock, CBE, professor of hematology-oncology at the University of Birmingham and consultant hematologist at University Hospitals Birmingham, shares his thoughts on the ASH 2025 meeting, including trial results from the paradigm study.
ASH 2025
Acute Myeloid Leukemia
News
Prof. Charles Craddock, CBE, discusses paradigm trial, transplant advances at ASH 2025
Related Post
SOHO 2026, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Aggressive B-Cell Lymphomas, Indolent B-Cell Lymphomas, Mantle Cell Lymphoma, T-Cell Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Neoplasms, Society Updates
Registration now open for SOHO 2026, receive early bird
March 31, 2026
